Evaluation of the Efficacy and Safety of a Plant-derived Combination Drug in Women with Localized Urinary Tract Infections

Urinary tract infections (UTIs) encompass a wide range of clinical and pathological conditions affecting different parts of the urinary system. There are different classification systems for UTIs. In order to improve consistency in clinical practice and to develop a holistic concept of the clinical manifestations of UTIs, the European Association of Urologists (EAU) 2025 Guidelines Working Group has proposed a new classification scheme. It does not use the terms “complicated” and “uncomplicated” UTIs. The emphasis is on the differences between localised and systemic UTIs, which are defined by clinical signs and symptoms. The 2025 EAU Guidelines recommend to consult the patients about the possibility of limited antibiotic use approach for the treatment and prevention of acute and recurrent cystitis. Patients should be fully informed about the evidence level for the different approaches, including non-antibiotic therapy as an alternative in non-geriatric patients, with shared decision-making between the physician and patient. The objective: to study the therapeutic potential of a plant-derived combination drug as monotherapy in women with symptomatic and asymptomatic localised UTIs. Materials and methods. The study included 112 female patients aged 18 to 65 years (average age is 37.4 ± 2.1 years). Among them 57 patients had symptomatic localised UTIs and 55 patients – asymptomatic localised UTIs. All patients were prescribed a plant-derived combination drug containing a thick extract of a mixture of liquid extracts: – Daucus carota L., fructus (wild fruit carrots) – 1:1; – Humulus lupulus L., flos (hops cone) – 1:1; – Origanum vulgare L., herba (herb mother) – 1:1 (in ratio 1:1.4:1, extractant – ethanol 96% v/v, calcucated on 10% moisture – 10.70 mg); – Mentha × piperita L., aetheroleum (olium pepper mint) – 7.46 mg; – Abies sibirica L., aetheroleum (Siberian egg oil) – 25.50 mg. The drug was prescribed 1 capsule 3 times a day for 7 days. The total duration of the study was 1 month. To assess the therapeutic efficacy and tolerability of the study drug, patients were examined using the following methods: history taking, objective examination, general urine analysis. Efficacy criteria: elimination of lower urinary tract symptoms (for symptomatic localised UTI), absence of lower urinary tract symptoms (for asymptomatic localised UTI); normalization of general urine analysis parameters (for symptomatic and asymptomatic localised UTI); number of patients who did not require antibiotic therapy (for symptomatic and asymptomatic localised UTI). Results. High efficacy, safety and good tolerability of the combined herbal preparation were found in symptomatic localized UTI (acute cystitis) in 78.9% of patients, moderate – in 8.8%. The need for antibacterial therapy was only in 12.3% of patients who retained lower urinary tract symptoms after the 3rd day of treatment and the presence of pathological changes in general urine analysis. In asymptomatic localised UTIs, high treatment effectiveness was in 83.6% of patients, moderate effectiveness – in 16.4%. None of the patient with asymptomatic UTI required antibacterial therapy, which confirms the therapeutic and prophylactic potential of the combined herbal preparation. Conclusions. Plant-derived combination drug which contains thick extract of rare extracts from Daucus carota L., fructus (wild fruit carrots) (1:1); Humulus lupulus L., flos (hops cone) (1:1); Origanum vulgare L., herba (herb mother) (1:1) in ratio 1:1.4:1, extractant – ethanol 96% v/v, calculated on 10% moisture – 10.70 mg; Mentha × piperita L., aetheroleum (olium pepper mint) – 7.46 mg; Abies sibirica L., aetheroleum (Siberian egg oil) – 25.50 mg, is an effective and safe agent in the treatment of localised UTIs (symptomatic and asymptomatic).